TIMOTHY DAVIS: Open Payments
NPI 1619377199 · HERNANDO, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,504 in 52 payments from 13 companies in 2025. Trend: 2023 $2,520 · 2024 $829 · 2025 $1,504
Food & beverage: $1,504
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 17 | $583 |
| Novo Nordisk Inc | 11 | $293 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $160 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $123 |
| AstraZeneca Pharmaceuticals LP | 6 | $100 |
| PFIZER INC. | 4 | $67 |
| Antares Pharma, Inc. | 2 | $44 |
| Xeris Pharmaceuticals, Inc. | 2 | $38 |
| Abbott Laboratories | 1 | $23 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $21 |
Products named: QULIPTA, UBRELVY, JARDIANCE, Ozempic, Kerendia, LINZESS, Wegovy, NURTEC ODT.
Industry payments across MS — which companies pay providers there.
